166 related articles for article (PubMed ID: 32003412)
1. HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer.
Couderc AL; Muracciole X; Nouguerede E; Rey D; Schneider S; Champsaur P; Lechevallier E; Lalys L; Villani P
J Nutr Health Aging; 2020; 24(2):205-209. PubMed ID: 32003412
[TBL] [Abstract][Full Text] [Related]
2. HoSAGE: sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: study protocol for a cohort trial.
Couderc AL; Villani P; Berbis J; Nouguerède E; Rey D; Rossi D; Lechevallier É; Badinand D; Bastide C; Karsenty G; Boissier R; Amichi K; Muracciole X
BMC Cancer; 2022 Jan; 22(1):78. PubMed ID: 35042460
[TBL] [Abstract][Full Text] [Related]
3. Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
Calcif Tissue Int; 2019 Oct; 105(4):403-411. PubMed ID: 31317232
[TBL] [Abstract][Full Text] [Related]
4. Effects of androgen deprivation therapy on elderly men with high-risk prostate cancer: PROSARC observational study.
Legido-Gómez Ó; Rico-Marco S; Lorenzo-Sánchez MV; Navarro-Jiménez S; Tárraga-Honrubia MA; Martínez-Ruiz J; Giménez-Bachs JM; Donate-Moreno MJ; Díaz de Mera-Sánchez-Migallón I; Segura-Martín M; Alcantud-Córcoles R; Abizanda-Soler P; Salinas-Sánchez AS
Actas Urol Esp (Engl Ed); 2024 May; 48(4):304-310. PubMed ID: 38373481
[TBL] [Abstract][Full Text] [Related]
5. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
Dawson JK; Dorff TB; Todd Schroeder E; Lane CJ; Gross ME; Dieli-Conwright CM
BMC Cancer; 2018 Apr; 18(1):368. PubMed ID: 29614993
[TBL] [Abstract][Full Text] [Related]
6. Moderators of resistance-based exercise programs' effect on sarcopenia-related measures in men with prostate cancer previously or currently undergoing androgen deprivation therapy: An individual patient data meta-analysis.
Lopez P; Newton RU; Taaffe DR; Winters-Stone K; Galvão DA; Buffart LM
J Geriatr Oncol; 2023 Jun; 14(5):101535. PubMed ID: 37229882
[TBL] [Abstract][Full Text] [Related]
7. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
[TBL] [Abstract][Full Text] [Related]
8. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case-control study.
Cheung AS; Gray H; Schache AG; Hoermann R; Lim Joon D; Zajac JD; Pandy MG; Grossmann M
J Cachexia Sarcopenia Muscle; 2017 Feb; 8(1):102-112. PubMed ID: 27897410
[TBL] [Abstract][Full Text] [Related]
10. Strength training induces muscle hypertrophy and functional gains in black prostate cancer patients despite androgen deprivation therapy.
Hanson ED; Sheaff AK; Sood S; Ma L; Francis JD; Goldberg AP; Hurley BF
J Gerontol A Biol Sci Med Sci; 2013 Apr; 68(4):490-8. PubMed ID: 23089339
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
12. The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer.
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1036-1044. PubMed ID: 31067013
[TBL] [Abstract][Full Text] [Related]
13. Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.
Gonzalez BD; Jim HSL; Small BJ; Sutton SK; Fishman MN; Zachariah B; Heysek RV; Jacobsen PB
Support Care Cancer; 2016 May; 24(5):2201-2207. PubMed ID: 26563183
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy before or during androgen-deprivation therapy does not blunt the exercise-induced body composition protective effects in prostate cancer patients: A secondary analysis of two randomized controlled trials.
Newton RU; Mavropalias G; Fragala MS; Kraemer WJ; Häkkinen K; Taaffe DR; Spry N; Joseph D; Galvão DA
Exp Gerontol; 2021 Aug; 151():111427. PubMed ID: 34052346
[TBL] [Abstract][Full Text] [Related]
15. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
[TBL] [Abstract][Full Text] [Related]
16. Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer.
Alberga AS; Segal RJ; Reid RD; Scott CG; Sigal RJ; Khandwala F; Jaffey J; Wells GA; Kenny GP
Support Care Cancer; 2012 May; 20(5):971-81. PubMed ID: 21538098
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia during androgen-deprivation therapy for prostate cancer.
Smith MR; Saad F; Egerdie B; Sieber PR; Tammela TL; Ke C; Leder BZ; Goessl C
J Clin Oncol; 2012 Sep; 30(26):3271-6. PubMed ID: 22649143
[TBL] [Abstract][Full Text] [Related]
18. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy.
Nilsen TS; Raastad T; Skovlund E; Courneya KS; Langberg CW; Lilleby W; Fosså SD; Thorsen L
Acta Oncol; 2015 Nov; 54(10):1805-13. PubMed ID: 25927504
[TBL] [Abstract][Full Text] [Related]
19. Prostate tumor-derived GDF11 accelerates androgen deprivation therapy-induced sarcopenia.
Pan C; Jaiswal Agrawal N; Zulia Y; Singh S; Sha K; Mohler JL; Eng KH; Chakkalakal JV; Krolewski JJ; Nastiuk KL
JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32078585
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
Boevé L; Hulshof MCCM; Verhagen PCMS; Twisk JWR; Witjes WPJ; de Vries P; van Moorselaar RJA; van Andel G; Vis AN
Eur Urol; 2021 Feb; 79(2):188-197. PubMed ID: 32978014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]